The Common Toxicity Criteria (CTC) define adverse events following cancer therapy. It was designed for use in clinical trials of different therapeutic regimens.
Types of sexual and reproductive adverse events for females:
(1) female sterility
(2) irregular menses
(3) vaginal dryness
Types of sexual and reproductive adverse events for males:
(1) erectile impotence
(2) male infertility
Types of sexual and reproductive adverse events for both females and males:
(1) libido
(2) other sexual or reproductive function
NOTES:
(1) Dyspareunia is graded in the "Pain" category.
(2) Dysmenorrhea is graded in the "Pain" category.
(3) Feminization of the male is graded in the "Endocrine" category.
(3) Masculinization of the female is graded in the "Endocrine" category.
Grade 0: normal or no change
|
Parameter |
Finding |
Grade |
|
vaginal dryness |
absent (normal) |
0 |
|
|
mild |
1 |
|
|
requires treatment and/or interferes with function and/or dyspareunia |
2 |
|
irregular menses (change from baseline) |
normal menses |
0 |
|
|
occasionally irregular or lengthened interval but cycles continue |
1 |
|
|
very irregular but menstrual cycle continues |
2 |
|
|
persistent amenorrhea |
3 |
|
female sterility |
absent (normal fertility) |
0 |
|
|
sterile |
3 |
|
erectile impotence |
normal erectile function |
0 |
|
|
mild (erections impaired but satisfactory) |
1 |
|
|
moderate (erection impaired, unsatisfactory for intercourse) |
2 |
|
|
no erections |
3 |
|
male infertility |
absent (normal fertility) |
0 |
|
|
oligospermia |
2 |
|
|
azoospermia |
3 |
|
libido |
normal |
0 |
|
|
decrease in interest |
1 |
|
|
severe loss of interest |
2 |
|
other |
none |
0 |
|
|
mild |
1 |
|
|
moderate |
2 |
|
|
severe |
3 |
|
|
disabling |
4 |
Specialty: Hematology Oncology, Urology
